Viridian Therapeutics (VRDN) is up 4.4% today. Here is some analysis on what might have caused this price movement.
Analysis: The most likely driver appears to be fresh bullish analyst coverage on November 19, which added support to a stock that already had positive momentum from recent pipeline data and an encouraging commercial update. Recent interest has centered on the company’s thyroid eye disease franchise, early LUMVOA launch traction, and favorable Phase 1 results for VRDN-008.
Details:
Sources:
Viridian Therapeutics, SEC, Google Finance
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$VRDN Insider Trading Activity
$VRDN insiders have traded $VRDN stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $VRDN stock by insiders over the last 6 months:
- JENNIFER TOUSIGNANT (Chief Legal Officer) has made 0 purchases and 2 sales selling 14,212 shares for an estimated $348,194.
To track insider transactions, check out Quiver Quantitative’s insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
EARLY ACCESS
Receive VRDN Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
$VRDN Hedge Fund Activity
We have seen 131 institutional investors add shares of $VRDN stock to their portfolio, and 123 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RTW INVESTMENTS, LP added 4,910,126 shares (+inf%) to their portfolio in Q3 2026, for an estimated $101,099,494
- POINT72 ASSET MANAGEMENT, L.P. added 2,290,336 shares (+97.7%) to their portfolio in Q3 2026, for an estimated $47,158,018
- CALIGAN PARTNERS LP added 2,193,981 shares (+inf%) to their portfolio in Q2 2026, for an estimated $40,303,430
- DEEP TRACK CAPITAL, LP removed 1,881,710 shares (-52.4%) from their portfolio in Q3 2026, for an estimated $38,744,408
- CITADEL ADVISORS LLC added 1,841,674 shares (+4458.9%) to their portfolio in Q3 2026, for an estimated $37,920,067
- FISHER ASSET MANAGEMENT, LLC removed 1,750,850 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $36,050,001
- CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM removed 1,592,132 shares (-94.8%) from their portfolio in Q3 2026, for an estimated $32,781,997
To track hedge funds’ stock portfolios, check out Quiver Quantitative’s institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$VRDN Analyst Ratings
Wall Street analysts have issued reports on $VRDN in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a “Buy” rating on 11/19/2026
- Wedbush issued a “Outperform” rating on 11/10/2026
- Wells Fargo issued a “Overweight” rating on 11/10/2026
- Leerink Partners issued a “Outperform” rating on 11/05/2026
- RBC Capital issued a “Outperform” rating on 11/05/2026
- Truist Securities issued a “Buy” rating on 11/05/2026
- Evercore ISI Group issued a “Outperform” rating on 11/05/2026
To track analyst ratings and price targets for $VRDN, check out Quiver Quantitative’s $VRDN forecast page.
$VRDN Price Targets
Multiple analysts have issued price targets for $VRDN recently. We have seen 9 analysts offer price targets for $VRDN in the last 6 months, with a median target of $41.0.
Here are some recent targets:
- Daniel Giraldo from B of A Securities set a target price of $47.0 on 11/19/2026
- Laura Chico from Wedbush set a target price of $44.0 on 11/10/2026
- Derek Archila from Wells Fargo set a target price of $39.0 on 11/10/2026
- Thomas Smith from Leerink Partners set a target price of $54.0 on 11/05/2026
- Lisa Walter from RBC Capital set a target price of $41.0 on 11/05/2026
- Gregory Renza from Truist Securities set a target price of $42.0 on 11/05/2026
- Maneka Mirchandaney from Evercore ISI Group set a target price of $33.0 on 11/05/2026
This article is not financial advice. See Quiver Quantitative’s disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.